Reviewing ReWalk Robotics (RWLK) & Delcath Systems (DCTHD)

ReWalk Robotics (NASDAQ: RWLK) and Delcath Systems (OTCMKTS:DCTHD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares ReWalk Robotics and Delcath Systems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ReWalk Robotics -346.14% -568.25% -90.30%
Delcath Systems -1,278.64% -3,960.73% -165.16%

Analyst Ratings

This is a breakdown of current recommendations and price targets for ReWalk Robotics and Delcath Systems, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ReWalk Robotics 1 0 3 0 2.50
Delcath Systems 0 0 0 0 N/A

ReWalk Robotics currently has a consensus price target of $3.38, suggesting a potential upside of 206.82%. Given ReWalk Robotics’ higher possible upside, equities analysts plainly believe ReWalk Robotics is more favorable than Delcath Systems.

Valuation and Earnings

This table compares ReWalk Robotics and Delcath Systems’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ReWalk Robotics $5.87 million 5.42 -$32.50 million ($1.59) -0.69
Delcath Systems $1.99 million 0.12 -$17.97 million ($1,377.67) 0.00

Delcath Systems has lower revenue, but higher earnings than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

3.2% of ReWalk Robotics shares are held by institutional investors. 13.7% of ReWalk Robotics shares are held by insiders. Comparatively, 0.0% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

ReWalk Robotics has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of -0.59, suggesting that its share price is 159% less volatile than the S&P 500.

Summary

ReWalk Robotics beats Delcath Systems on 11 of the 12 factors compared between the two stocks.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.

Delcath Systems Company Profile

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

What are top analysts saying about ReWalk Robotics Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ReWalk Robotics Ltd and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit